title: Challenges in the assessment of erectile dysfunction and treatment with oral therapies: review with case examples.
abstract: OBJECTIVE
  To review the clinical dimensions, etiology, assessment, and treatment of erectile dysfunction (ED) and to increase awareness of oral therapies for this condition.
  
  
  METHODS
  Scientific literature, consensus guidelines, and manufacturers' product information and guidelines.
  
  
  CONCLUSIONS
  A prevalent condition, particularly in middle-aged and elderly men, ED is vastly underreported and undertreated. Oral therapies, including phosphodiesterase type 5 inhibitors, are effective and well tolerated in many patients and represent potential first-line treatments for ED.
  
  
  CONCLUSIONS
  ED has been associated with both life-threatening illnesses and reduced quality of life. Improving recognition and treatment of this condition and counseling patients about ED represent important clinical opportunities. A broad and expanding array of ED treatments enable therapy to be individualized to the needs of patients and their partners.
authors.affiliation: Erectile Dysfunction Clinic, Veterans Affairs Medical Center, Minneapolis, Minnesota, USA. jean.lewis@med.va.gov
authors.forename: Jean H
authors.initials: JH
authors.lastname: Lewis
mesh_terms: D000368:Aged; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000209:etiology; D015984:Causality; D003376:Counseling; D003937:Diagnosis, Differential; D007172:Erectile Dysfunction / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D008487:Medical History Taking; D008875:Middle Aged; D009722:Nurse Practitioners; D009730:Nursing Assessment; D018579:Patient Selection; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000600:supply & distribution / Q000627:therapeutic use; D010808:Physical Examination; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D018570:Risk Assessment; D012449:Safety; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000494:pharmacology / Q000600:supply & distribution / Q000627:therapeutic use
chemical_list: D010726:Phosphodiesterase Inhibitors; D014665:Vasodilator Agents